|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM353029572 |
| 003 |
DE-627 |
| 005 |
20231226055051.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109265
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1176.xml
|
| 035 |
|
|
|a (DE-627)NLM353029572
|
| 035 |
|
|
|a (NLM)36796471
|
| 035 |
|
|
|a (PII)S1521-6616(23)00044-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Looney, Cary M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.03.2023
|
| 500 |
|
|
|a Date Revised 18.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Targeted B-cell depletion is a useful therapy for many diseases, including autoimmune disorders and certain cancers. We developed a sensitive blood B-cell depletion assay, MRB 1.1, compared its performance with the T-cell/B-cell/NK-cell (TBNK) assay, and assessed B-cell depletion with different therapies. The empirically defined lower limit of quantification (LLOQ) for CD19+ cells in the TBNK assay was 10 cells/μL, and 0.441 cells/μL for the MRB 1.1 assay. The TBNK LLOQ was used to compare differences between B-cell depletion in similar lupus nephritis patient populations who received rituximab (LUNAR), ocrelizumab (BELONG), or obinutuzumab (NOBILITY). After 4 weeks, 10% of patients treated with rituximab retained detectable B cells vs 1.8% with ocrelizumab and 1.7% for obinutuzumab; at 24 weeks 93% of patients who received obinutuzumab remained below LLOQ vs 63% for rituximab. More-sensitive measurements of B cells may reveal differences in potency among anti-CD20 agents, which may associate with clinical outcomes
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a B cells
|
| 650 |
|
4 |
|a B-cell depletion
|
| 650 |
|
4 |
|a CD19
|
| 650 |
|
4 |
|a CD20
|
| 650 |
|
4 |
|a Flow cytometry
|
| 650 |
|
4 |
|a High-sensitivity flow cytometry
|
| 650 |
|
7 |
|a Rituximab
|2 NLM
|
| 650 |
|
7 |
|a 4F4X42SYQ6
|2 NLM
|
| 700 |
1 |
|
|a Strauli, Nicolas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cascino, Matthew D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Garma, Hailey
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schroeder, Aaron V
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takahashi, Chikara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a O'Gorman, William
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Green, Cherie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Herman, Ann E
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 248(2023) vom: 10. März, Seite 109265
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:248
|g year:2023
|g day:10
|g month:03
|g pages:109265
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109265
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 248
|j 2023
|b 10
|c 03
|h 109265
|